Immunization of mice with a recombinant vaccinia virus expressing the human papillomavirus type 16 (HPV-16) E6 gene elicits specific antibody, proliferative and cytotoxic T lymphocyte responses. T and B cell epitopes were mapped by using synthetic peptides. This study provides the background to future investigation aimed at developing prophylactic and therapeutic vaccines against HPV-16 infection and cervical cancer.
Introduction
Cancer of the cervix is one of the most common cancers in women, and there is now considerable epidemiological, histopathological and molecular evidence showing that some types of human papillomaviruses (HPV), notably HPV type 16, are aetiologically associated with the disease (zur Hausen & Schneider, 1987) . The antigenicity of HPV-16 E6 protein is of particular interest, because the expression of open reading frames (ORFs) E6 and E7 is necessary and sufficient for transformation of human cells by HPV-16 (Schlegel et al., 1988; Pirisi et al., 1987; Storey et al., 1988) and these two early viral proteins are found in a variety of turnout cells of the cervix (Seedorf et al., 1987) . Recent studies have shown that HPV E6 protein can bind to and promote degradation of cell-encoded turnout suppressor p53 (Crook et al., 1991; Scheffner et al., 1990) .
Unlike some other HPV types, it has not been possible to propagate HPV-16 either in vitro or in laboratory animals (Taichman et al., 1987) . In addition, human HPV-16 lesions contain few virions, also limiting the availability of native HPV-16 proteins. However, molecular biological techniques have made it possible to express viral proteins for immunological studies. Vaccinia virus (VV) has been extensively used in the eradication of smallpox (Behebani, 1983) . Although not completely innocuous, the virus has long been considered safe for human use and has also been used successfully as t Present address: Department of Immunology, Windeyer Building, Cleveland Street, London WC1 6DB, U.K. a vector for the expression of foreign genes (Mackett et al., 1982) . Despite some disadvantages, the use of recombinant vaccinia virus (rVV) as a live vaccine against infectious and malignant diseases has therefore been proposed.
We constructed an rVV expressing HPV-16 E60RF and studied the response to this construct in mice. We show that the rVV elicits antibody, T cell proliferative and cytotoxic T cell (CTL) responses to this antigen, and we have identified a number of major antigenic epitopes recognized within the protein.
Methods
Synthetic peptides. A series of 10-mer peptides, overlapping by five residues, of HPV-16 E6 protein was synthesized on a DuPont RAMPS multiple peptide synthesis apparatus using conventional solid phase fluoren-9-ylmethoxycarbonyl (Fmoc) chemistry. The HPLC profile was determined for all peptides.
Animals and bweulation procedures. Female, 8 to 10-week old specific pathogen-free DBA/2 (H-2 ~) and C57BL (H-2 ~) mice were obtained from the ICRF Animal Unit, Clare Hall, Potters Bar, U.K., and maintained in a negative pressure isolator after immunization. The rVV was inoculated (1.6 x l0 t p.f.u./dose) onto the base of the tail area by scarification and produced visible cutaneous lesions within 3 days; a second inoculation was given 10 days later. The control animals received the same doses of wild-type (wt) VV strain WR.
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[ Directio~ranscription Fig. 1 . A schematic representation of rVV16 E6/360. The HPV-16 E6 gene was subcloned into the serpin site downstream of a synthetic promoter to produce the new rVV. 824R, VV serpin gene; P7.5, VV 7.5K promoter; P360, synthetic promoter.
confirmed by direct sequencing. It was then cloned into plasmid p360 containing a synthetic VV early promoter (TAAAAATTGAAAAAT-TAGCTCTATTTATTGCAC) or plasmid pUC42K containing another synthetic VV early promoter (CCCGAGCTCTAAAACACAT-AAAAATAAGCGTAACTAATAAGACAAGGTACCCC) based on a consensus VV promoter region as described by Davison & Moss (1989) . The E6/promoter sequence was transferred to VV expression vector pSX3 (Zhou et al., 1990) to produce pSX360E6 (E6 driven by the synthetic early promoter) and pSX42KE6 (by the 42K early promoter) in which the E6 gene and the selection marker Escherichia coli GPT gene (Coupar e/al., 1988 ; Falkner & Moss, 1988) , are flanked by a VV serine protease inhibitor (serpin) gene, B24R (Kotwal & Moss, 1989; Smith et al., 1989) . This construct was transfected into wt VVinfected CV-1 cells. Recombination between the homologous sequences of the serpin gene in both the insert and VV resulted in the recombinational transfer of the expression block to the VV genome. These recombinants were selected by growth in the presence of mycophenolic acid at a concentration of 25 gg/ml. Virus plaques were purified twice in CV-1 cells. The HPV-16 rVVs were named rVV16E6/360 (code name 360E6VV from plasmid pSX360E6) and rVVI6E6/42K (code name 42KE6VV from plasmid pSX42KE6).
Detection of HPV-16 E6 protein.
HPV-16 E6 gene-transfected (see below) or rVV16E6/360-infected cells were lysed in 1% NP40, nuclei were removed by centrifugation and the cytoplasmic fraction was solubilized in 2 % SDS and 2 % 2-mercaptoethanol before separation in a 15 % SDS-polyacrylamide gel. Protein was electrotransferred from the gels onto nitrocellulose filters (Amersham). The filters were incubated in 2 % casein to block non-specific binding sites and reacted with 1:50 rabbit anti-HPV-16 E6 or with E6 peptide polyclonal antibody (see below); reactions were developed with 1 : 1000 peroxidaseconjugated swine anti-rabbit IgG (Dako), and positive signals visualized using enhanced chemiluminescence (ECL, Amersham) and exposure to Kodak X-Omat film. The same technique was used to detect the generation of anti-HPV-16 E6 antibody in mice immunized with rVV. Sera were used at 1 : 100 as the first antibody and peroxidaseconjugated rabbit anti-mouse IgG at 1:1000 was then used as the second.
Generation of transfectants.
A PJ4f~ plasmid containing the whole HPV-16 E60RF, PJ4~16 E6 (Storey et al., 1988) , was introduced into P815, EL4, RMA and A20 cells by electroporation (using the Bio-Rad Gene Pulser). The cells were resuspended in MEM and electroporated in a 1 ml cuvette at a concentration of 107/ml, with 10 lag PJ4~16 E6 plasmid and 1 lag of a pSV2 neomycin resistance plasmid. The cells were electroporated at a field strength of 0.45 kV and were then cultured in complete medium containing 1 mg/ml G418 for selection, cloned by limiting dilution and tested for E6 expression by ECL Western blotting.
Production oJ~oolyclonal antibodies to E6. Since antibodies to terminal peptides have been shown to be superior to those against internal regions in binding to both native and denatured proteins (Friedrich et al., 1986) , a carboxy-terminal peptide from the HPV-16 E6 sequence (amino acids 141 to 150, RSSRTRRETQ) was chosen for anti-peptide antibody production. The peptide was coupled to keyhole limpet haemocyanin using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (Sigma) as cross-linker, dialysed against PBS, mixed 1 : 1 with RIBI adjuvant (Universal Biologicals) and used as antigen for immunization of rabbits (half Lop from ICRF Animal Unit, Clare Hall) following the manufacturer's protocol. Antibody against the peptide was detected in an ELISA using the corresponding peptide as antigen. Antiserum was also generated to whole E6 protein. HPV-16 E6-glutathione-S-transferase (GST) fusion protein was expressed in E. coli by insertion of the HPV-16 E6 gene into the pGEX-3X (Pharmacia) expression plasmid. The GST-portion was cleaved by digestion with factor Xa and E6 protein was purified by gel filtration. The purified protein was used as an antigen in immunization following the same protocol. Antibody raised against the whole protein recognized the corresponding protein produced by rVVE6-infected A20 (Fig. 2) and both antibodies detected E6 in transfected cells by Western blot analysis (Fig. 3) .
Mapping of B cell epitopes. Epitope analysis was carried out by ELISA in flat-bottomed 96-well plates (Nunc) coated with 10 gg/well of synthetic HPV-16 E6 peptide in 0.1 M-Na2CO 3 pH 9.6, for 2 h at room temperature; the plates were washed three times with PBS Tween 20 (0.05 % v/v; BDH) and then blocked with 3 % BSA in Tris-HC1-buffered saline for 2 h at room temperature. Dilutions of the sera from immunized mice were incubated in the wells for 2 h, washed off and developed with alkaline phosphatase-conjugated rabbit anti-mouse IgG (Dako, 1:1000) for 1 h at room temperature. The plates were washed, p-nitrophenyl phosphate (Sigma) as substrate was added, and incubated for 1 h at room temperature. Absorbance at 405 nm was determined in a 96-well spectrophotometer (Dynatech).
Cell proliferation assay. Ten days after a second inoculation with rVV or wt VV the draining inguinal and peri-aortic lymph nodes were taken and passed through a nylon mesh to produce a single-cell suspension that was then washed twice in MEM. Viable cells were counted and resuspended at 2 x 106 cells/ml in RPMI 1640 medium supplemented with 1% normal mouse serum and 2-mercaptoethanol (1 x 10 -5 M). Synthetic HPV-16 E6 peptides and a control peptide (corresponding to the HPV-16 E7 amino acids 1 to 10) were diluted in PBS to give final concentrations of 0.016 to 5 ~tM. Peptides or concanavalin A (Con A; 10 lag/ml) were added to flat-bottomed 96-well tissue culture plates (Nunc) containing 2 x l0 b lymph node cells/well; controls containing medium only were also included. The cells were then incubated at 37 °C in a 5 % CO 2 humidified atmosphere for 4 days and pulse-labelled with 1 laCi [aH]thymidine (Amersham) per well for 16 h prior to harvesting onto glass filters using an automatic cell harvester. The amounts of thymidine incorporated into the cells were measured by liquid scintillation (LKB Betaplate). All cultures were carried out in triplicate, and standard errors were less than 20 % of the mean.
Antigen-specific CTL assay. DBA/2 (H-2 ~) and C57BL (H-2 b) mouse spleens were harvested 10 days after the animals had been primed with rVV16E6/360 or wt VV. Single-cell suspensions at 1 x 105/ml were restimulated in vitro with 1 x 104/ml irradiated (5000 rad) HPV-16 E6 gene-transfected syngeneic cells, for 8 days in vitro in RPMI 1640 medium containing 10% fetal calf serum and 2-mercaptoethanol (l x 10 .5 M). Cytolytic activity of secondary CTLs in vitro was measured as previously described (Zhou et al., 1990) , using a 4 h 51Cr release assay. Briefly, 104 SlCr-labelled target cells were mixed and incubated for 4 h at 37 °C with different numbers of CTLs in a final volume of 0.2 ml medium. For testing the epitope specificity of CTLs, effectors were co-cultured with peptide-pulsed targets at a 90:1 ratio. 51Cr release for each point was calculated from the mean radioactivity detected in triplicate samples, and the data are presented using the formula: percentage specific 5~Cr release = 100 x [(experimental release-spontaneous release)/(maximum release -spontaneous release)]. Maximum release was determined from supernatants of target cells that had been lysed by addition of 5% Triton X-100. Spontaneous release was determined from supernatants of target cells incubated without added effector cells.
Results
Expression of HPV-16 E6 protein
To confirm expression of HPV-16 E6 by rVV, A20 cells infected with 5 p.f.u./cell rVV16E6/360 were harvested at 3 h, 6 h, 12 h, 18 h and 24 h post-infection (p.i.) and lysed. The cell lysates were analysed by SDS-PAGE and Western blotting with the anti-E6 protein rabbit serum. Fig. 2 illustrates that a major 18K band corresponding to HPV-16 E6 protein was expressed in A20 cells as early as 3 h p.i. There was no band at the equivalent position in the uninfected cell lysate or in cells infected with wt VV (data not shown). A weaker band at an M~ of approximately 36K was also seen in some infected but not uninfected cell lysates, possibly corresponding to incomplete denaturation of an E6 dimer, or E6 complexed with some other cellular protein.
Antibody response to E6
The development of E6-specific antibody was evaluated by immunoblotting using sera taken 10 days after the second immunization from rVV16E6/360-infected mice.
The results obtained are shown in Fig. 3 (a) . The sera were tested against A20/E6 transfectants or untransfected A20 cells. A band of approximately 18K corresponding to E6 protein was detected in the transfected but not the parent cells when sera from three animals immunized with rVV16E6/360 were used. The presence of this band was specific for cells transfected with E6, and therefore did not represent a non-specific reaction. None of the five animals given the control wt VV developed antibody against HPV-16 E6 (not shown). For comparison, Fig. 3 (b) shows the reactivity of polyclonal rabbit antisera raised against either whole recombinant E6 protein (lanes 3 to 6 and 9 to 14) or against the E6 Cterminal peptide (lanes 1, 2 and 7, 8). The data shown in this figure also confirm the expression of E6 protein in A20, P815, EL4 and RMA cells transfected with the E6 ORF. Reactivity (A4o5) of the sera in ELISA with a series of synthetic 10-met overlapping peptides and E6 protein expressed in transformed E. coli.
Peptide numbers corresponding to the HPV-16 E6 sequences are indicated, e.g. 1 represents 1-10, 6 represents 6-15, etc. The solid line is drawn at an A value corresponding to three times the mean of all the sera from the wt VV-infected mice. Sera giving A values above this line were considered to give positive binding.
. 
Identification of B cell epitopes
Candidate linear B cell epitopes were identified by testing immune sera taken from rVV16E6/360-inoculated mice against a series of overlapping E6 peptides by ELISA. Fig. 4 shows the results from a typical experiment. The pooled sera from five rVV16E6/360-inoculated mice reacted with six peptides (absorbance values greater than three times the mean of the control sera from wt VVinfected mice) corresponding to candidate linear B cell epitopes (residues 86 to 95, 96 to 100, 111 to 120, 136 to 140, 141 to 146 and 146 to 150). Three of these peptides were clustered at the C terminus of the protein. Sera from five mice infected with another recombinant, rVV16E6/ 42K (with a 42K promoter instead of p360 synthetic promoter), also recognized the same peptides (data not shown). Sera from wt VV-infected mice identified a weakly cross-reactive peptide (residues 11 to 20).
Proliferative response qf T cells to HPV-16 E6 peptides
To study whether HPV-16 E6 peptides are capable of eliciting a helper T cell response, the ability of these peptides to induce specific proliferation in vitro in lymph node cells from rVV-primed mice was determined. Proliferative responses of lymph node cells from C57BL mice immunized with rVV16E6/360 to a series of overlapping E6 peptides are shown in Fig. 5 . The results show that peptides 41-50, 91-100 and 146-151 induced specific proliferation, significantly above that of cells without peptide and of that with the same dose of irrelevant peptide, E7 1-10. The rest of the E6 peptides gave no significant proliferation above that of the medium and peptide controls. Concentrations as low as 0.016 gM of E6 peptide 41-50 induced a significant response (data not shown) suggesting this peptide contains a potent proliferative T cell epitope. Cells from mice immunized with wt VV gave no significant response to any E6 peptides (not shown). Attempts to measure proliferative responses in DBA/2 H-2 d mice were not successful.
CTL response to HPV-16 E6
To determine whether CTLs against HPV-16 E6 can be elicited by immunizing the animals with rVVE6/360, spleen cells from C57BL (H-2 b) mice and DBA/2 (H-2 d) mice were restimulated in vitro with E6 transfectants of the appropriate haplotype, A20E6 (H-2 d) and EL4E6 (H-2"°). Expression of E6 in the transfectants was confirmed in each case by ECL Western blotting (see Fig.  3b ). After one or more rounds of restimulation, the responding T cells were assayed on the same or different transfectants of the same haplotype (Fig. 6) . To exclude the possibility that the lysis of transfected cells was due to their being more fragile than the non-transfected cells, a transfectant line expressing an irrelevant protein was also used as control targets in some experiments. Fig. 6 shows that rVV16E6/360-primed immune spleen cells elicited an E6-specific response in both haplotypes of mice tested. Although the response was mainly haplotype-specific, some weak cross-reaction on E6-expressing allogenic targets was frequently observed (see Fig. 6b ) perhaps reflecting weak natural killer or lymphokine-activated killer cell reactivity in the cultures. Spleen cells from wt VV-infected mice showed no specific killing of the HPV-16 E6-transfected cells (Fig. 6c) . 
Fine specificity of specific CTLs for E6
E6-specific CTL populations generated as described above were assayed on P815 cells or RMA cells incubated with individual peptides from a set of overlapping 10-mer peptides which covered the E6 sequence. As shown in Fig. 7 , specific cell lysis could be elicited with specific peptides for each haplotype. The wt VV did not prime cells for any of the E6 peptides. There was no overlap between the peptide repertoire in the two strains. Furthermore, the cells from the rVV16E6/360-primed H-2 b mice recognized the peptide 131-140 only in the context of presenting cells expressing the autologous major histocompatibility complex (MHC) molecules, and not when the same peptide was presented on cells of the H-2 d haplotype (Fig. 8) .
Discussion
The high incidence of cervical cancer (zur Hausen & Schneider, 1987) highlights the need for an HPV vaccine.
In this study, we have demonstrated that an rVV, rVV16E6/360 bearing the HPV-16 E6 sequence, can be used to stimulate both antibody and T cell responses specific for the E6 protein. Further studies will be required to test whether the findings in this mouse model are applicable to humans, especially as our study used a non-licensable, and potentially more immunogenic strain of VV. Three proliferative epitopes and three CTL epitopes were identified in the two haplotypes tested. Several major linear antibody epitopes were also identified. The E6 protein of HPV-16 is a good candidate for a target tumour antigen for immunotherapy or immunoprophylaxis of cancer of the cervix, since its distribution is highly specific and mRNA for E6 is found in a high proportion of cervical high grade neoplasias (Higgins et al., 1992) . Studies in rats have shown that immunization with E6 VV recombinants can indeed partially protect against tumour challenge (Meneguzzi et al, 1991) . Since it is an intracellular protein, it is unlikely that antibody responses will provide effective protective or curative responses for HPV infection. However, a previous study suggested that antibodies to HPV early protein E7 are markers for invasive cervical cancer (Mann et al., 1990) . In our studies we have found that antibody responses to E6 protein give a highly restricted response to a few epitopes, which are found predominantly in the Cterminal portion of the molecule. Since our study uses short overlapping peptides to identify antibody-binding sites, it is likely that we are missing responses to other conformational determinants on the molecule. However, our results do suggest that there are a number of strongly immunogenic linear epitopes within the E6 molecule, which perhaps correspond to antigenic loops on the surface of the protein, and may have a relatively high degree of mobility within the overall structure (Tainer et al., 1985) . The identification of these epitopes may provide useful information for clinical studies using synthetic peptides to identify anti-E6 antibodies in human sera.
In contrast to humoral responses, T cells are likely to be the dominant effector cell in effective responses to E6. However, it is still unclear whether optimum protection can be provided by CD8 + class I-restricted CTLs, or CD4 + class II-restricted 'inflammatory' T cells. There is some evidence in animal models that E6-or E7-expressing tumours can be controlled by cytotoxic T cell responses (Chen et al., 1991 (Chen et al., , 1992 . However, inflammatory T cells clearly play an important role in regression of non-malignant HPV warts (Benton et al., 1992) . For this reason we tested for both proliferative responses (which are predominantly CD4 + class II-restricted responses) and for class I-restricted CD8 + cytolytic responses. Because we did not have a sufficiently pure source of E6 protein, we tested for proliferative responses only to the panel of E6 peptides. Using mice expressing the H-2 b haplotype, we identified two peptides inducing strong proliferative responses following rVV immunization. In contrast, our attempts to find responses to epitopes in mice of the H-2 ' 1 haplotype were unsuccessful. One possible reason for this failure may be because the length of the peptides used in these assays, which was optimized for CTL responses, is rather shorter than the optimal size of class II MHC-binding peptides (Rudensky et al., 1992) . Thus weak proliferation-inducing epitopes in this strain may have gone unnoticed. However, our results stress the restricted nature of the proliferative T cell response to a relatively small protein such as E6.
The cytotoxic response against E6 transfectants proved to be as restricted in repertoire as the proliferative response since only three positive peptides were identified in the two strains of mice tested. This finding is in agreement with a number of other studies demonstrating the restricted nature of the CTL response against complex protein antigens (Townsend et al., 1986) . The factors that operate to govern this repertoire remain undefined. However, in a previous paper we have analysed in detail the MHC class I (H-2 ~') binding ability of all the E6 peptides, and the ability of these peptides, on their own, to stimulate a CTL response (Stauss et al., 1992) . Unexpectedly, there appears to be no correlation between binding of the peptides to H-2K and H-2D molecules in vitro, and their ability to act as epitopes in rVVE6-primed mice. The reasons why the peptide binding assay used in our previous study did not detect the binding of these peptides to class I MHC molecules are not yet clear. In addition, we were unable to identify any of the previously described allele-specific peptide motifs (Falk et al., 1991) in either the H-2 d (TTLEQQYNKP and QRHLDKKQRF) or H-2 b (RWTGRCMSCC) haplotype. One possibility, at least in H-2 d mice, is that the cytolytic response is restricted by H-2L, a class I molecule which has been analysed much less intensively.
Our results have a number of important implications in terms of the design of vaccines for HPV-16. Firstly, we believe that our results demonstrate that it is unwise to rely solely on either theoretical predictions (based on motifs) or even class I binding assays in identifying potential peptide epitopes for vaccine design. Secondly, our results confirm that the T cell immune response to a protein is limited to a very few epitopes, dictated by the haplotype of the host. This phenomenon imposes severe restraints on the use of synthetic peptides as immunogens in outbred human populations. It raises the possibility that several haplotypes may exist that recognize no E6 epitopes at all, although the expression of six class I MHC molecules in human (outbred) populations make it tess likely that an individual would be unable to mount any response to E6. Finally, the restricted nature of the response, particularly to a small protein such as E6, compounds the difficulties due to sequence variability among HPV types, since mutations at single loci may be sufficient to convert an immunogenic protein to a nonimmunogenic variant.
In conclusion, our study presents a detailed analysis of the immunological responses to a recombinant VV construct expressing the E6 protein. Since there is not yet an animal model of HPV infection, it is difficult to test the effectiveness of the responses generated in controlling viral infection. Studies in rats have shown that VV E6 recombinants partially protect against tumour challenge (Meneguzzi et al., 1991) , and turnout protection studies in mice are already in progress in our laboratory. Nevertheless, our study provides further evidence that E6-expressing cells can process and present peptide epitopes derived from this oncogene in such a way as to be recognized by E6-specific cytotoxic T cells (Chert et al., 1992) . Furthermore, we clearly demonstrate that the recombinant vectors used are capable of stimulating both proliferative and cytotoxic responses. A combination of these two cell types may be important in achieving maximum effectiveness in vivo.
This study has provided a valuable example of the multi-disciplinary approach which is an essential component of HPV immunology. The lack of viral culture systems, and the consequent need to generate all viral components synthetically, poses considerable logistical problems in terms of vaccine development. In addition, it has proved essential to produce antibody reagents which can be used routinely to screen for HPV protein expression in the many molecular constructs which have been used for this study, since both transfectants and the VV constructs themselves were able to lose expression. A co-ordinated molecular, immunological and virological programme will be an absolute prerequisite in the development of effective immunological therapies for HPV.
